PMID- 26989641
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2167-9312 (Print)
IS  - 2167-9320 (Electronic)
IS  - 2167-9312 (Linking)
VI  - 1
IP  - 3
DP  - 2013 Sep
TI  - Evaluation of Chitosan-Tripolyphosphate Nanoparticles as a p-shRNA Delivery 
      Vector: Formulation, Optimization and Cellular Uptake Study.
PG  - 266-278
AB  - Polysaccharides (especially chitosan) have recently attracted much attention as 
      gene therapy delivery vehicles for their unique properties such as 
      biocompatibility, biodegradability, low toxicity, and controlled release. 
      Nanoparticles have strong potential as a carrier of plasmid short hairpin RNA 
      (p-shRNA). This study aimed to find the optimum conditions for obtaining 
      Chitosan/triphosphate (TPP)/p-shRNA nanoparticles by the ionic gelation method, 
      and investigating the cellular uptake of the optimized nanoparticles. After 
      applying the central composite design of response surface methodology (RSM), the 
      optimum conditions for preparation of nanoparticles with small size and high 
      loading efficiency were: chitosan/TPP ratio = 10, pH = 5.5 and N/P ratio = 11. 
      The resulting nanoparticles had an average size of 172.8 +/- 7 nm and loading 
      efficiency of 71.5 +/- 5%. SEM images showed spherical and smooth nanoparticles. 
      The nanoparticles complexed with p-shRNA and may protect it against nuclease 
      digestion. Cytotoxicity studies with HeLa and PC3 human cancer cells demonstrated 
      that chitosan/TPP nanoparticles had low toxicity. Cellular uptake studies using 
      HeLa cells showed that the nanoparticles entered the cells (cellular uptake) and 
      delivered DNA, probably due to their favorable Zeta potential (approximately +28 
      mV) and small size.
FAU - Karimi, Mahdi
AU  - Karimi M
AD  - Department of Nanobiotechnology, Faculty of Biological Sciences, Tarbiat Modares 
      University, Tehran, 14115, Iran; Department of Dermatology, Wellman Center for 
      Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston MA, 
      02114, USA.
FAU - Avci, Pinar
AU  - Avci P
AD  - Department of Dermatology, Wellman Center for Photomedicine, Massachusetts 
      General Hospital, Harvard Medical School, Boston MA, 02114, USA; Department of 
      Dermatology, Semmelweis University School of Medicine, Budapest, 1085, Hungary.
FAU - Ahi, Mohsen
AU  - Ahi M
AD  - Biotechnology Group, Faculty of Chemical Engineering, Tarbiat Modares University, 
      Tehran, 14115, Iran.
FAU - Gazori, Tarane
AU  - Gazori T
AD  - Biotechnology Group, Faculty of Chemical Engineering, Tarbiat Modares University, 
      Tehran, 14115, Iran.
FAU - Hamblin, Michael R
AU  - Hamblin MR
AD  - Department of Dermatology, Wellman Center for Photomedicine, Massachusetts 
      General Hospital, Harvard Medical School, Boston MA, 02114, USA; Harvard-MIT 
      Division of Health Sciences and Technology, Cambridge, MA, 02139, USA.
FAU - Naderi-Manesh, Hossein
AU  - Naderi-Manesh H
AD  - Department of Nanobiotechnology, Faculty of Biological Sciences, Tarbiat Modares 
      University, Tehran, 14115, Iran; Department of Biophysics, Faculty of Biological 
      Sciences, Tarbiat Modares University, Tehran, 14115, Iran.
LA  - eng
GR  - R01 AI050875/AI/NIAID NIH HHS/United States
PT  - Journal Article
DEP - 20130901
PL  - United States
TA  - J Nanopharm Drug Deliv
JT  - Journal of nanopharmaceutics and drug delivery
JID - 101671470
PMC - PMC4792291
MID - NIHMS735058
OTO - NOTNLM
OT  - Cellular Uptake
OT  - Chitosan
OT  - Gene Delivery
OT  - Nanoparticle
OT  - Response Surface Methodology (RSM)
OT  - p-shRNA
EDAT- 2013/09/01 00:00
MHDA- 2013/09/01 00:01
PMCR- 2016/03/15
CRDT- 2016/03/19 06:00
PHST- 2016/03/19 06:00 [entrez]
PHST- 2013/09/01 00:00 [pubmed]
PHST- 2013/09/01 00:01 [medline]
PHST- 2016/03/15 00:00 [pmc-release]
AID - 10.1166/jnd.2013.1027 [doi]
PST - ppublish
SO  - J Nanopharm Drug Deliv. 2013 Sep;1(3):266-278. doi: 10.1166/jnd.2013.1027. Epub 
      2013 Sep 1.